KURA Q2 2022 Earnings — Kura Oncology, Inc. Revenue & Financial Results | Market Cap Arena

KURAKura Oncology, Inc.

$815M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$35M

Net Income

-$35M

EPS (Diluted)

$-0.52

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$31M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$471M

Total Liabilities

$22M

Stockholders' Equity

$449M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$35M	-$34M	-5.0%
Net Income	-$35M	-$34M	-3.3%